Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18978361 | Liquid supramolecular self-recognition system of low-pH azelaic acid, and preparation method therefor and application thereof | December 2024 | April 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18613633 | Methods For Treating Pancreatic Cancer Using Combination Therapies | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18565586 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | November 2023 | November 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 17824421 | Methods For Treating Pancreatic Cancer Using Combination Therapies | May 2022 | June 2025 | Allow | 36 | 1 | 0 | No | No |
| 17693425 | PROCESS FOR MAKING A SKINCARE PRODUCT | March 2022 | April 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17636453 | PROCESS AND COMPOSITION MATTER OF NANOPARTICLE FORMULATION FOR SYSTEMIC TREATMENT OF SEPSIS | February 2022 | August 2023 | Allow | 18 | 0 | 0 | No | No |
| 17627512 | LONG-ACTING FORMULATIONS AND VEHICLES | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17626289 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING A TRIPTAN | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17623432 | LAYERED COLLAGEN DRESSING WITH EXTENDED BACTERIA AND BIOFILM REDUCING CAPABILITIES | December 2021 | February 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17452041 | DUAL TARGETING AND THERAPEUTIC NANOPARTICLE FOR TREATING RENAL FIBROSIS | October 2021 | November 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17434776 | STABILIZER CONCENTRATES FOR WAX DISPERSIONS | August 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17458975 | FACIAL TREATMENT SYSTEMS AND METHODS | August 2021 | February 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17459728 | Therapeutic Agent and Nutraceutical Compositions And Methods for Making and Using Same | August 2021 | February 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17405866 | POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION | August 2021 | January 2024 | Allow | 29 | 2 | 0 | No | No |
| 17431448 | PHARMACEUTICAL FORMULATIONS | August 2021 | August 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17390568 | Slippery Liquid-Infused Porous Surfaces that Release Hydrophilic and Hydrophobic Agents | July 2021 | July 2023 | Allow | 24 | 1 | 0 | No | No |
| 17426535 | Nano composite material aiming at acidic sealing zone in osteoclasts and preparation method thereof | July 2021 | August 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17443040 | HOOF MUD COMPOSITION | July 2021 | August 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17421959 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | July 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17370408 | BIODEGRADABLE FOAM SUBSTRATE FOR GROWING PLANTS, PLANT SYSTEM PROVIDED THEREWITH, AND METHOD FOR MANUFACTURING SUCH SUBSTRATE | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17419227 | DRUG-DELIVERING NERVE WRAP | June 2021 | May 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17418139 | SOLID COSMETIC COMPOSITION CONTAINING AQUEOUS SPHEROIDS DISPERSED IN A SOLID CONTINUOUS ANHYDROUS PHASE | June 2021 | June 2025 | Allow | 47 | 3 | 0 | Yes | No |
| 17418155 | BIO-COATING AND IMPLANT | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17418009 | SHORT-ACTING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | June 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17312796 | FILAMENTOUS NANOPARTICLES HAVING VACCINE ADJUVANT EFFECT | June 2021 | November 2024 | Allow | 41 | 2 | 1 | No | No |
| 17320945 | DIHYDROMYRICETIN SPRAY-DRIED DISPERSION FORMULATIONS AND METHODS FOR FORMING THEM | May 2021 | November 2024 | Abandon | 42 | 3 | 0 | No | No |
| 17319971 | AGGREGATED MICROPARTICLES | May 2021 | January 2024 | Allow | 32 | 0 | 0 | No | No |
| 17292649 | COMPOUND DELIVERY SYSTEMS AND METHODS OF PRODUCTION | May 2021 | February 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17289416 | COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES WITH ACETOLACTATE SYNTHASE (ALS) INHIBITOR HERBICIDES | April 2021 | September 2024 | Allow | 41 | 1 | 0 | No | No |
| 17288688 | NANOPARTICLE/HYDROGEL COMPLEXT FOR DRUG CARRIER | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17281811 | Silicic Acids for Use in the Treatment of Periodontitis | March 2021 | September 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17280606 | GLYMPHATIC DELIVERY BY MANIPULATING PLASMA OSMOLARITY | March 2021 | March 2025 | Allow | 48 | 4 | 0 | Yes | No |
| 17271284 | Tetrathionate for Cyanide and Methylmercaptan Poisoning | February 2021 | June 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17266889 | DRUG DELIVERY PRODUCT, COMPOSITION AND SYSTEM | February 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17266201 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND USES THEREOF | February 2021 | January 2025 | Allow | 48 | 4 | 0 | No | No |
| 17264563 | STABILIZER-CONTAINING SOLID DRUG FORMULATION | January 2021 | May 2024 | Allow | 39 | 4 | 0 | No | No |
| 17264199 | CONTROLLED RELEASE FORMULATIONS WITH LIGNIN FOR AGROCHEMICALS | January 2021 | October 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17263706 | A NOVEL AQUEOUS COMPOSITION WITH WATER INSOLUBLE VITAMINS | January 2021 | September 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17261858 | CONTROLLED RELEASE FORMULATION COMPRISING FLAVOXATE | January 2021 | January 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17149684 | SIRTUIN 1 ACTIVATION AGENT AND SKIN COSMETIC FOR ACTIVATING SIRTUIN 1 | January 2021 | August 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17259470 | BIOLOGICAL METHODS FOR CONTROLLING PHYTOPATHOGENIC FUNGI | January 2021 | May 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17252452 | FUNGICIDALLY ACTIVE COMBINATION OF A CLONOSTACHYS STRAIN AND AN AZOLE | December 2020 | August 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17058358 | Method for producing Cu-embedded plastic masterbatches | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17056190 | ADHESIVE COMPOSITION AND ADHESIVE PATCH | November 2020 | May 2024 | Abandon | 42 | 2 | 0 | No | No |
| 16976303 | FORMULATIONS | August 2020 | February 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16975701 | POWDER PREPARATION, CARTRIDGE, AND DEVICE | August 2020 | April 2025 | Allow | 56 | 4 | 0 | Yes | No |
| 16967032 | HERBICIDE COMPOSITION CONTAINING PYRIMIDINEDIONE-BASED COMPOUND | August 2020 | March 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16606456 | THERAPEUTIC PROTEIN-LOADED NANOPARTICLE AND METHOD FOR PREPARING THE SAME | October 2019 | February 2025 | Abandon | 60 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MACH, ANDRE works in Art Unit 1615 and has examined 46 patent applications in our dataset. With an allowance rate of 45.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner MACH, ANDRE's allowance rate of 45.7% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MACH, ANDRE receive 1.67 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MACH, ANDRE is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +59.5% benefit to allowance rate for applications examined by MACH, ANDRE. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.